Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2024-12-03 00:00:00 ET · period of report 2024-11-29 · accession 0000914475-24-000222 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-03 | 2024-11-29 | NBIX | Onyia Jude | CSO | S - Sale+OE | $126.29 | -2,331 | 15.4K | -13% | -$294.4K |
| D | 2024-12-03 | 2024-11-29 | NBIX | Onyia Jude | CSO | M - OptEx | $0.00 | +4,426 | 17.8K | +33% | $0 |
| D | 2024-12-03 | 2024-11-29 | NBIX | Onyia Jude | CSO | M - OptEx | $0.00 | -4,426 | 4,426 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-29 | S | D | 2,331 | $126.29 | 15,449 | D | — | — | (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.42 to $127.04. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. (F3) Includes an aggregate of 226 shares purchased on February 29, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2024-11-29 | M | A | 4,426 | $0.00 | 17,780 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2024-11-29 | M | D | 4,426 | $0.00 | 4,426 | D | — · — to — | 4,426 Common Stock | (F4) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F5) This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and will vest as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award. |